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2Abstract
Abdominal aortic aneurysms (AAA) are characterized by matrix remodeling, elastin degradation, 
absence of nitric oxide (NO) signaling, and inflammation, influencing smooth muscle cell (SMC) 
phenotype and genotype. Little is known about the biomolecular release and intrinsic 
biomechanics of human AAA-SMCs. NO delivery could be an attractive therapeutic strategy to 
restore lost functionality of AAA-SMCs by inhibiting inflammation and cell stiffening. We aim to 
establish the differences in phenotype and genotype of adult human AAA-SMCs from healthy 
SMCs. Based on our previous study which showed benefits of optimal NO dosage delivered via 
S-Nitrosoglutathione (GSNO) to healthy aortic SMCs, we tested whether such benefits would 
occur in AAA-SMCs. The mRNA expression of three genes involved in matrix degradation 
(ACE, ADAMTS5 and ADAMTS8) was significantly downregulated in AAA-SMCs. Total protein 
and glycosaminoglycans synthesis were higher in AAA-SMCs than healthy-SMCs and was 
enhanced by GSNO and 3D cultures. Elastin gene expression, synthesis and deposition, 
desmosine crosslinker levels, and lysyl oxidase (LOX) functional activity were lower, while cell 
proliferation, iNOS, LOX and fibrillin-1 gene expressions were higher in AAA-SMCs, with 
differential benefits from GSNO exposure. GSNO and 3D cultures reduced MMPs -2, -9, and 
increased TIMP-1 release in AAA-SMC cultures. AAA-SMCs were inherently stiffer and had 
smoother surface than healthy SMCs, but GSNO reduced stiffness (~25%) and increased 
roughness of both cell types. In conclusion, exogenously-delivered NO offers an attractive 
strategy by providing therapeutic benefits to AAA-SMCs.
Key Words: abdominal aortic aneurysm, elastin, matrix proteins, cell modulus, MMPs, nitric 
oxide, LILAS study
31. Introduction
Chronic vascular pathological conditions (e.g., hypertension, atherosclerosis, trauma, 
infection) promote localized release of proteinases and enzymes which break down the intact 
extracellular matrix (ECM; e.g., elastin, glycosaminoglycans (GAGs)) within the adult abdominal 
aortic walls [1; 2]. Unfortunately, the major cell types in aorta, i.e., smooth muscle cells (SMCs) 
and adventitial fibroblasts, are limited in their ability to repair, replace or regenerate the 
degraded vascular matrix, which often results in progressive weakening and burgeoning of 
blood vessel diameter (> 50% increase relative to healthy vessel) – a condition clinically termed 
as abdominal aortic aneurysm (AAA). AAAs are also typically characterized by the presence of 
innate and adaptive immune cells (e.g., macrophages, T-cells, neutrophils, lymphocytes) which 
release abnormal levels of cytokines and matrix metalloproteinases (MMPs) to exacerbate the 
breakdown of elastic fibers and other matrix proteins [3; 4]. This, in turn, disrupts the signaling 
between elastic fibers and SMCs, promotes SMC apoptosis, and weakens elasticity in blood 
vessel walls, to permanently alter the mechanical properties and native microenvironment of the 
vessel wall [5; 6].
Among the major ECM components native to blood vessels, collagen, GAGs and elastin 
play an important role in regulating cell adhesion, anchoring, proliferation, and migration [4; 7]. 
They also regulate blood vessel homeostasis by supporting axial and circumferential loadings 
and conferring anti-thrombogenic properties [8]. These ECM molecules are synthesized, 
crosslinked, and deposited as mature matrix fibers by SMCs and adventitial fibroblasts within 
the aorta. While the turnover of collagens and GAGs is maintained even through adolescence, 
elastic matrix fiber deposition primarily occurs only during developmental stages and preserved 
throughout the adult life (elastin half-life is ~74 years) [9]. Since healthy elastic fibers play critical 
biochemical and biomechanical roles in maintaining vessel homeostasis, abnormalities in elastin 
4formation due to genetic defects or elastin degradation due to diseases could result in peptides 
formation, which invalidates the beneficial role of intact elastic fibers [10; 11].
Given the limitations of existing surgical (e.g., endovascular aneurysm repair, open surgery), 
pharmacological (e.g., anti-inflammation agents, beta-blockers, statins) and preservation (e.g., 
MMPs inhibition, TIMPs delivery, elastases suppression) interventions for comprehensive AAA 
treatment [9; 12; 13; 14; 15], ECM (specifically elastin) repair and regeneration approaches 
focusing on tissue-engineered grafts, stem cells, 3D scaffolds, bimolecular cues, biomechanics, 
and their combinations, are being explored [16; 17]. We have recently reported on the benefits 
of delivering exogenous nitric oxide (NO) cues via S-nitrosoglutathione (GSNO), to cell 
proliferation and ECM deposition by adult human aortic SMCs (Hu-SMCs) within 3D biomimetic 
cocultures with adult human endothelial cells (Hu-ECs) [18]. While the phenotype and genotype 
of ECM proteins synthesized by healthy Hu-SMCs has been reported [19; 20; 21; 22], similar 
outcomes from their AAA-counterparts are unknown. Specifically, the baseline levels of matrix 
proteins synthesized and deposited by human AAA-SMCs, changes in their phenotype and 
genotype, the cytokines and chemokines released, their stiffness levels, and the responses to 
exogenous biomolecular cues, remains unexplored. Such information is critical for 
understanding the disease etiology and identify effective pharmacological, tissue engineering 
and regenerative medicine strategies to repair and regenerate elastin in AAA vessels.
In this study, we first investigated the changes in transcription levels of AAA-SMC genes, 
involved in the pathological progression of this disease. Next, we assessed the in vitro baseline 
levels of cell proliferation, phenotypic and genotypic expression, ECM and biomolecular (elastin, 
sulfated glycosaminoglycans (sGAGs), hyaluronan (HA), LOX, desmosine, inducible nitric oxide 
synthase - iNOS) synthesis and deposition, release of cytokines/ chemokines/ MMPs/ TIMPs, 
and biomechanical characteristics of human AAA-SMCs. Similar outcomes from healthy Hu-
SMCs were assessed under identical culture conditions for comparison. Finally, the response of 
5AAA-SMCs to exogenously-delivered NO cues was evaluated and compared to their healthy 
counterparts, to establish the utility of delivering exogenous NO for AAA treatment.
2. Materials and Methods
2.1. Population study
LILAS was a case-control study that enrolled 42 men, some with AAA, who needed a 
vascular surgery or endovascular treatment at the Lille University Hospital Centre (Lille, France) 
between September 2003 and July 2005 [23]. Case patients were considered eligible if the AAA 
diameter, measured by abdominal ultrasound exceeded 50 mm, or if it had increased more than 
10 mm during the past six months and required initial surgical treatment. The study conformed 
to the principles outlined in the Declaration of Helsinki, ethics committee of the Lille University 
Hospital Centre (France) approved the study, and each patient provided written informed 
consent. Clinical data items were presented as mean ± SD, and frequencies with proportions as 
appropriate. Statistical significance was assigned at p < 0.05.
2.2. Isolation of human AAA-SMCs
Aortic samples (Fig. 1A) were obtained for 20 of the 24 AAA patients and SMCs were 
isolated from all the 20 AAA tissue samples. Individual cultures of AAA-SMCs were established 
for each patient by dissection of a residual segment of abdominal aorta and then cutting out the 
media into 1-2 cu.mm pieces and culturing them on type 1 collagen coated dishes (rat tail-
derived, BD Biosciences, France) in medium 231 supplemented with smooth muscle growth 
supplement (Cascade Biologics, France) and antibiotics (50 µg/mL streptomycin, 50 U/mL 
penicillin; Sigma-Aldrich). SMCs were characterized by western blot analysis. Twenty 
microgram fractions of cell lysates were separated by SDS-PAGE (9% polyacrylamide), 
transferred to Hybond C membranes (GE Healthcare, France) and blotted with antibodies 
against α-smooth muscle actin (α-SMA) (1A4, Dako, 1:5000), fibronectin (E3A, Sigma-Aldrich, 
61:3000), and vinculin/ meta-vinculin (hVIN-1, Sigma-Aldrich, 1:400). The blots were 
subsequently washed in PBS-Tween 20 and incubated with appropriate secondary antibodies 
(peroxidase-conjugated anti-mouse IgG, GE Healthcare) at a dilution of 1:5000. The blots were 
then washed three times in PBS-Tween 20 for 15 min, incubated with enhanced 
chemiluminescence reagents (GE Healthcare), and exposed to a radiographic film scanned with 
an Imagescanner® (GE Healthcare). AAA-SMCs were subsequently passaged with Medium 
231 (Life Technologies).
2.3. Transcriptomic analysis of human AAA-SMCs
Changes in SMCs were validated for selected genes with qRT-PCR. RNA samples isolated 
from SMCs were converted to cDNA with an in vitro transcription reaction. We used cDNA as 
templates for Taqman qRT-PCR with ABI Assays-on-Demand on an ABI Prism 7900 sequence 
detection system. The specific assays were designed by TaqMan® Gene Expression Assays 
(Applied Biosystems) and used Hs 00199841-m1 (ADAMTS 5), Hs 00199836-m1 (ADAMTS 8), 
Hs 00166915-m1 (renin), Hs 00174179-m1 (ACE1), and Hs 00377632-m1 (L-cathepsin). All 
samples were run in triplicate, with GADPH (Hs99999905_m1) and Cyclophilin A 
(Hs99999904_m1) as internal controls to normalize transcript abundance (2-dCt method). 
Triplicates were averaged to calculate an expression value for each sample.
2.4. Human AAA and healthy aortic SMC cultures
AAA-SMCs derived from one patient (details in Table 1) were investigated further using 
biochemical and biomechanical analysis to establish the baseline. Healthy adult Hu-SMCs 
isolated from a 16-year old male were obtained from Life Technologies Corp. (Carlsbad, CA, 
USA) and passaged using Medium 231 (ThermoFisher Scientific, USA). For experiments in this 
study, cells from passages 3-5 for healthy cells and 2-3 for AAA cells were used. AAA-SMCs 
were cultured on 2D collagen-coated (50 µg/mL) substrates or within 3D collagen hydrogels (2 
mg/mL; pH ~ 7.2). Results from 2D substrates will help establish the baseline values, while 
7cultures in 3D gels will provide more physiological-mimic microenvironment. Cells were cultured 
for 21 days in SMC media, containing 100 nM GSNO (Sigma, Saint-Louis, MO, USA), a NO 
donor. Control cultures received no GSNO (termed 0 nM). Healthy and AAA-derived SMCs 
were imaged at random locations during passaging using a Zeiss Axiovert A1 florescence 
microscope equipped with Hamamatsu camera and image acquisition software. At least ten 
images per cell type were processed using ImageJ (NIH) to quantify the perimeter and area of 
each cell type.
Table 1. Baseline characteristics of the study population in AAA group. AAA: aortic abdominal 
aneurysm; CAD: coronary artery disease; MI: myocardial infarction; ACS: acute coronary 
syndrome; PTCA: percutaneous transluminal coronary angioplasty. Data expressed as mean  
SD, where appropriate.
AAA
(n = 24)
Age, years 68.0±6.1
Male gender, % 24 (100)
Anthropometric data,
Weight, kg
Height, cm
Body mass index, kg/m2
82.9±11.6
173.8±5.4
27.4±3.7
Cardiovascular risk factors, n (%)
Current smoking
Past smoking
Hypercholesterolemia
Hypertension
Diabetes mellitus
Familial history of CAD
4 (17)
17 (71)
14 (58)
15 (63)
4 (17)
4 (17)
Personal history of CAD, n (%) Stable 
Angina,
MI or ACS,
Coronary artery bypass,
PTCA,
2 (8)
7 (29)
1 (4)
4 (17)
History of stroke, n (%) 0
Two sets of cultures were performed in parallel. 3D collagen gels were prepared by mixing 
collagen stock solution (type 1, rat-tail derived, BD Biosciences, Bedford, MA, USA) with a 
mixture of 10 PBS, 1 M NaOH and deionized water. For 3D cultures, SMCs were mixed in 
8collagen gels at a density of 104 cells per well in 48-well plates. The cultures were placed in a 
humidified incubator (37 °C, 30 min) to polymerize the collagen gels. For 2D cultures, collagen-
coated 24-well tissue culture plastic plates were seeded with 104 cells per well. GSNO dose 
used in this study was identified from our previous study [18] where a range of GSNO doses 
were tested to evaluate their effects on ECM synthesis and deposition. Media was changed 
once every two days and the spent medium was pooled over the 21-day culture and stored at -
20 °C for further biochemical analyses. Similarly, cell matrix layers at the end of 21 days were 
trypsinized and processed for biochemical assays.
2.5. Biochemical assays
At the end of 21 days, the amounts of various protein types released into the pooled media 
or deposited within cell matrix of 2D and 3D cultures were quantified as detailed earlier [18]. 
Individual biochemical assays were performed on AAA-SMC cultures to quantify total protein 
(BCA Kit Assay; Sigma-Aldrich), elastin (Fastin assay; Accurate Scientific Corp, Westbury, NY), 
sulfated glycosaminoglycans (sGAGs; Kamiya Biomedical Company, Seattle, WA), and HA 
(hyaluronan enzyme-linked immunosorbent quantitative assay; Echelon Biosciences Inc., Salt 
Lake City, UT) amounts. For BCA assay, the protein amounts within cells was not separated 
from the total protein quantified within cell layers. However, the protein content in 2 mg/mL 
collagen gels (3D cultures) and collagen-coated 2D cultures was quantified (without cells) using 
this assay and deducted from the protein amounts reported in test cases. Although other 
proteins such as collagens might be released and deposited by SMCs, their amounts were not 
assessed here. SMC proliferation was quantified using a fluorometric assay detailed earlier[18], 
to quantify the amount of DNA synthesized over the 21 days. Similarly, LOX functional activity 
was quantified using a fluorometric assay (AmplexRed® Assay; Molecular Probes, Eugene, 
OR).
2.6. Desmosine bioassay
9The amount of desmosine produced and released by AAA-SMCs and healthy SMCs into the 
pooled media was quantified using a sandwich enzyme immunoassay technique (Human 
Desmosine ELISA Kit; MyBioSource, Inc., San Diego, CA). The desmosine bioassay has a 
detection range of 0.1-10 ng/mL and a sensitivity of 0.039 ng/mL. Briefly, aliquots of samples 
and standards were incubated in a 48-strip-well pre-coated with desmosine-specific antibody, 
and the bound desmosine was serially-tagged with biotin-conjugated DES-specific antibody and 
avidin-conjugated horseradish peroxidase, with intermediate washings after every step. Finally, 
desmosine amounts in each sample were assessed calorimetrically based on the intensity of 
color generated within a substrate solution in proportion to the respective DES amounts.
2.7. Real-time PCR analysis of SMCs
For RT-PCR analysis, AAA-SMCs and healthy SMCs were cultured in parallel on 2D 
collagen-coated substrates or within 3D collagen gels and exposed to 100 nM GSNO for 5 days 
to induce changes in gene expression, and GSNO-free cultures served as controls. Total RNA 
was extracted from SMCs using RNAqueous®-Micro total RNA isolation kit (Life technologies) 
according to the manufacturer’s instructions. The RNA concentration of each sample was 
determined using a NanoDrop ND-1000 spectrophotometer (Thermo Scientific, Wilmington, 
DE). The RNA was reverse-transcribed to cDNA using the high-capacity cDNA reverse 
transcription kit with RNase inhibitor (Life Technologies) according to manufacturer’s 
instructions. Gene expression in SMCs was quantified using TaqMan® gene expression assays 
(Applied Biosystems), and TaqMan® Gene expression master mix for each target using the ABI 
7500 Real-time PCR System (Applied Biosystems, Forest City CA) limited to only 40 cycles. 
The following genes were analyzed: lysyl oxidase (LOX, Assay ID: Hs00942480_m1), elastin 
(ELN, Assay ID: Hs00355783_m1), fibrillin 1 (FBN1, Assay ID: Hs00171191_m1), and inducible 
nitric oxide synthase 2 (NOS2, Assay ID: Hs01075529_m1). To identify relative differences in 
the levels of target genes, gene expression in AAA-SMCs was normalized to endogenous 
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reference gene (18S, Assay ID: 4319413E) and further to corresponding expression in healthy 
SMCs, using the ∆∆Ct method.
2.8. Cytokine/ Chemokine assays
Cytokine, chemokine, TIMP and MMP analyses were performed using Discovery Assays® 
(Eve Technologies, Alberta Canada), from 2D or 3D cultures of AAA-SMCs and healthy SMCs. 
Briefly, cell culture supernatants were collected from each well after 24 h, spun down at 3000 g 
for 5 min, and stored at -20 °C. The supernatants were then processed using multiplexing 
LASER bead technology and processed on a dual-laser flow-cytometry system (Bio-Plex 200). 
The technology works by utilizing different combinations of red and infrared fluorophore beads 
conjugated to specific antibodies targeted to the cytokine or chemokine of choice and read 
using a flow-cytometry based system. The quantity of the specific analyte generated was based 
off a series of standards set forth by the company. The assays performed include human 
focused 11-plex, human MMP 9-plex and TIMP 4-plex, to quantify the following analytes: GM-
CSF, IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12 (p70), MCP-1, TNF-α, MMPs-1, 2, 3, 7, 8, 9, 
10, 12, 13, and TIMPs-2, 3, 4.
2.9. Western blot analysis of iNOS
iNOS expression within healthy and AAA-SMCs, in both 2D and 3D cultures, in the 
presence or absence of GSNO, was semi-quantitatively evaluated using western blot analysis 
[18]. To optimize loading sample volumes for SDS/PAGE western blot, cell pellets from 
respective cultures were assayed using a DC protein assay kit (Bio-Rad Labs). The protein 
bands were detected using a primary polyclonal antibody for the iNOS protein (Abcam), 
visualized using chemiluminescence method and quantified using ImageJ.
2.10. TIMP-1 assay
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TIMP-1 amounts released by healthy and AAA-SMCs into the pooled media, in the presence 
or absence of GSNO, were quantified using Human TIMP-1 Quantikine ELISA Kit (R&D 
Systems, Minneapolis, MN). Spent media (supernates) from the cell cultures in 2D or 3D were 
pooled and stored at -20 C, and loaded onto a 96-well polystyrene microplate coated with a 
monoclonal antibody specific for human TIMP-1. Post-incubation (2 h, RT) on a horizontal 
orbital shaker, the bound proteins were incubated with human TIMP-1 specific horseradish 
peroxidase-linked polyclonal antibody (1 h, RT), exposed to a chromogen solution containing 
tetramethylbenzidine for (30 min, RT, dark), and the reaction was stopped with 2 N sulfuric acid. 
Final solutions were measured using Epoch BioTek microplate spectrophotometer with 
absorbance at 450 nm. This assay has a range of 0.2-10 ng/mL in supernatant solutions, with a 
sensitivity of 0.08 ng/mL.
2.11. Immunofluorescence labeling of cell layers
AAA-SMCs were cultured on glass chamber slides (104 cells/well) for 21 days in the 
presence or absence of 100 nM GSNO, and the cell layers were fixed in cold methanol, washed 
with PBS, blocked with PBS containing 5% v/v goat serum (ThermoFisher Scientific) and 
immunolabeled with rabbit anti-human polyclonal antibodies against elastin (1:100 v/v dilution, 
Abcam), fibrillin-1 (1:100 v/v dilution, Bioss Antibodies), fibulin-4 (1:100 v/v dilution, Santa Cruz 
Biotechnology), and fibulin-5 (1:100 v/v dilution, Santa Cruz Biotechnology). Cell layers were 
washed with PBS and labeled with Alexafluor 633 goat anti-rabbit secondary antibody; 1:1000 
dilution, ThermoFisher Scientific). The cell layers were washed with PBS and mounted with 
Vectashield containing the nuclear stain 4',6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI; 
Vector Laboratories, Burlingame, CA). AAA-SMC layers treated with the secondary probe alone 
(no primary antibody) served as negative controls. Cell layers were imaged with a Leica SP8 
confocal microscope (Leica Microsystems Inc, Buffalo Grove, IL).
2.12. Atomic force microscopy (AFM) analysis of cell stiffness and roughness
12
Healthy and AAA-SMCs were cultured in 35-mm laminin-coated petri dishes and maintained 
at 37 °C throughout live-cell nanoindentation assay, over a 60-min experiment each time, 
performed using a MFP-3D-Bio AFM (Asylum Research, Santa Barbara, CA) mounted on an 
inverted optical microscope (Nikon Eclipse Ti). Tip-less AFM cantilevers (model Arrow TL 1, 
Nano World, nominal spring constant ~ 0.03 N/m) were modified by attaching a 4.5 μm 
polystyrene bead using epoxy [24]. The spherical bead indenter reduces the possibility of 
destructive deformation of cell due to smaller local strains applied [25], compensates for the x-y 
drift (usually < 1 μm), and yields higher spatially-averaged measurement with minimal variability, 
relative to conventional sharp-tip probes. The actual spring constant was determined from a 
force-distance curve and using thermal calibration method in a clean culture dish containing 
DMEM. Drifting minimization and thermal/mechanical equilibrium of AFM was achieved by 
submerging probe in cell medium for stabilization. For each experiment, at least 30 cells were 
randomly selected, indented between nuclei and cell edges, and 150-200 force curves were 
obtained per cell in force-volume mode, at a rate of 0.25 Hz with approach/ retraction velocity of 
2.5 µm/s. Using Hertz’s contact model [ , Young’s modulus was 𝐹 =  (4𝐸 𝑅𝛿3) 3(1 ‒ 𝜇2)]
determined from these force curves, where F is the indentation force, E is the Young’s modulus, 
µ is the Poisson’s ratio (0.5 for cells), R is radius of spherical bead attached to cantilever and  
is the indentation depth (300–400 nm) [25]. The analysis of force-indentation curves was 
automated using Igor Pro 6.37 software. The indentation data was analyzed assuming cells 
behave as linear elastic at small strain regimes. The mean elastic modulus values were 
calculated for each cell from the elastic modulus heat maps generated over randomly-selected 
90  90 m2 area, and then averaged across multiple cells for each culture condition group. 
From this data, the mean surface roughness (Ra) of each cell - characterized as the arithmetic 
mean of the deviations in height from the line mean value, and the root mean square (Rq), were 
calculated [26]. Both Ra and Rq were obtained from randomly selected areas (30  30 µm2) on 
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the cell membrane. A two-tailed Student’s t-test was applied to all the pairs of samples 
(untreated-treated cells) for statistical analysis and p < 0.05 were considered significant.
2.13. Statistical analysis
All biochemical data were obtained from three independent repeat experiments per case (n 
= 3 wells/ case/ experiment) and analyzed using one-way ANOVA followed by Tukey’s HSD 
post-hoc testing, assuming unequal variance and differences deemed significant for p < 0.05. 
The data were assumed to follow a near-Gaussian distribution in all the cases, and the mean 
and standard errors were calculated accordingly.
3. Results
3.1. Patients
Table 1 summarizes the baseline characteristics of the 42 AAA subjects. One-third of the 
AAA patients had hypertension, half had dyslipidemia, 17% had diabetes mellitus, and 29% had 
family members who had a history of heart disease (myocardial infarction and/or acute coronary 
syndrome). The AAA case patients (n=24) had a mean maximal external aortic diameter of 
56.1±11.3 mm (range: 46-95 mm). Fewer AAA patients received ACE inhibitor treatment (21% 
vs. 44%). None of the AAA patients took non-steroidal anti-inflammatory drugs (NSAIDs).
3.2. Primary AAA-SMC cultures
SMCs migrated from AAA explants after 10 days and reached confluence in one month. All 
the cultured AAA-SMCs had the same elongated, spindle-shaped morphology, and at 
confluence all cultures assumed a hill-and-valley pattern that was maintained throughout 
subcultures (Fig. 1A). Protein expression profiles determined by western blot analysis (Fig. 1A) 
showed that all the cultures from patient groups expressed α-SMA, vinculin and meta-vinculin, 
indicating the presence of differentiated SMCs. Fibronectin, a component of basement 
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membrane, was also expressed indicating a proliferative and secretory SMC phenotype. RT-
PCR analysis (Fig. 1B) indicated that mRNA expression of three genes appeared to be 
significantly down-regulated in SMCs from AAA patients: ACE (angiotensin converting enzyme), 
ADAMTS 5 and ADAMTS 8. The plots of individual mRNA expression for these three genes 
(normalized to house-keeping genes) shows the variability, with ADAMTS8 being the most 
suppressed.
Figure 1. (A) A sample AAA tissue (n = 20 patients) used for SMC cultures. Representative 
phase-contrast microscopy of SMCs obtained by explant from human AAA biopsies. Western 
blot analysis of SMC for fibronectin, meta-vinculin (160 kDa), vinculin (116 kDa) and α-smooth 
muscle actin (α-SMA). Scale bar: 100 m. (B) mRNA expression ratio of genes (2-dCt; 
normalized to house-keeping genes) in SMCs derived from AAA (n = 12) patients, potentially 
involved in matrix degrading processes in AAA, as determined by RT-PCR.
3.3. AAA-SMC proliferation and dimensions
Despite similar morphologies within 2D cultures, the area and perimeter of AAA-SMCs 
within 2D cultures were significantly higher compared to their healthy counterparts (Fig. 2A; 52 
<n<79; p<0.01 in both cases). The phenotype of AAA-SMCs was confirmed by staining for α-
actin in monolayer cultures, with more than 98% positive-stained cells. In general, AAA-SMC 
proliferation is significantly lower in 3D gels compared to their 2D counterparts (Fig. 2B). 
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Addition of GSNO significantly suppressed SMC proliferation in 3D gels with a trend in 2D 
counterparts.
Figure 2. (A) Representative phase-contrast images of adult healthy Hu-SMCs and AAA-SMCs 
cultured in this study. Significant differences in average cell area and perimeter were noted 
between the two cell types. Data shown represents mean ± standard error in respective cases. 
Scale bar: 200 m.  (B) Fold increase in AAA-SMC density within 2D (black histograms) and 3D 
(white histograms) cultures, in the presence or absence of exogenous 100 nM GSNO. Data 
shown represents mean ± standard error of cell count after 21 days of culture, normalized to 
initial seeding density (n = 3/ condition). Cell densities were quantified using a fluorometric 
assay detailed earlier. (C) Fold-changes (vs. GSNO-free controls) in total protein, elastin, 
sGAG, and HA, deposited within cell matrix or released into pooled media, by human AAA-
SMCs, in 2D and 3D cultures, in the presence of 100 nM GSNO. The total protein amounts 
were quantified using a BCA protein assay, elastin amounts using a Fastin Assay kit, sGAG 
amounts using a quantitative dye-binding sGAG assay kit, and HA amounts using a hyaluronan 
enzyme-linked immunosorbent quantitative assay. Quantitative results were obtained from cell 
matrix layers or pooled media after 21 days of culture and normalized to cell count within 
respective cases (n = 6/ condition). Data were analyzed using one-way ANOVA followed by 
Tukey’s HSD post-hoc testing, assuming unequal variance and differences deemed significant 
for p < 0.05 between respective cases. Data shown represents mean ± standard error in 
respective cases.
3.4. Total protein synthesis
Protein synthesis and release by AAA-SMCs has not been reported earlier. The total protein 
synthesized by AAA-SMCs, in 2D and 3D cultures, in the presence or absence of GSNO, was 
quantified as two separate components (Fig. 2C): protein deposited in the cell matrix (termed 
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matrix here) and protein released into the pooled media (termed media here). A significant 
increase in the total protein deposited in cell matrix was observed with GSNO addition, in both 
2D (2.58-fold) and 3D (3.1-fold) cultures. Total protein deposited in cell matrix within 3D cultures 
was significantly higher than that in 2D counterparts (p<0.01), in the presence or absence of 
GSNO (16.4-fold and 19.8-fold, respectively). GSNO stimulated significant increase in the total 
protein released into the pooled spent media in 3D cultures (p<0.01 vs. 2D). The amounts of 
protein in pooled media were at least two-orders of magnitude higher than in matrix, in all 
conditions. This study established the baseline for the total protein amounts released and 
deposited by adult human AAA-SMCs in 2D and 3D cultures (actual amounts provided in Table 
2), in the absence of any stimulation. However, less than 2% of total protein produced by AAA-
SMCs was deposited as matrix within cell layers, suggesting that additional approaches are 
required to coacervate the protein into matrix form. Compared to healthy SMCs (Table 2; 
Supplementary Fig. 1), the total protein deposited within 3D cell layers or released into the 
spent media by AAA-SMCs was significantly higher (i.e., 2-fold and 19-fold, respectively) even 
in the absence of GSNO. GSNO stimulated a 7-fold increase in protein deposition within matrix 
layers and a 17-fold increase in protein release within pooled media by AAA-SMCs within 3D 
cultures, compared to Hu-SMCs (Supplementary Fig. 1).
Table 2. Amounts of various proteins deposited in cell matrix or released into pooled media by healthy and AAA human aortic SMCs, 
on a per cell basis, over a 21-day period, within 2D or 3D cultures, in the presence or absence of 100 nM GSNO. Data shown here 
represents the average of at least n = 6/ case. Data for the healthy Hu-SMCs were from our previous publication [18].
Total protein 
amounts (μg) Elastin (ng) sGAGs (ng) HA (pg)
LOX functional 
activity (pM)GSNO 
dose (nM)
Fold-increase 
in proliferation, 
compared to 
initial seeding
Cell 
matrix
Pooled 
media
Cell 
matrix
Pooled 
media
Cell 
matrix
Pooled 
media
Cell 
matrix
Pooled 
media
Cell 
matrix
Pooled 
media
0 3.2 0.13 2.02 ND 7.06 ND 16.7 0.21 2.07 69 703D 
cultures
Healthy 
Hu-SMCs 100 2.03 0.12 3.12 1.31 29.9 0.49 7.08 0.5 3.2 370 1610
0 2.05 0.27 37.9 < 0.01 0.17 < 0.01 0.036 0.57 27.6 0.1 2.763D 
cultures
Hu-AAA-
SMCs 100 1.3 0.83 52.7 < 0.01 0.26 < 0.01 0.063 0.77 40.7 0.27 3.1
0 2.8 0.016 16.8 < 0.01 0.15 < 0.01 0.015 0.36 22.8 0.02 0.182D 
cultures
Hu-AAA-
SMCs 100 2.1 0.042 34.6 < 0.01 0.177 < 0.01 0.034 0.51 29.7 0.03 2.5
ND: Not detectable within assay limits (i.e., < 1 pg/cell amounts).
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Supplementary Figure 1. Normalizes protein synthesis by human AAA-SMCs in the presence 
or absence of GSNO, in 2D and 3D cultures. (A) Basal amounts of HA, sGAG, elastin, and total 
protein deposited within cell matrix or released into pooled media, by human AA-SMCs, in 2D 
(black histograms) or 3D (white histograms) cultures. (B) Similar proteins and GAGs deposited 
by AAA-SMCs in the presence of 100 nM GSNO. Data represents mean ± standard error of 
quantitative results obtained from cell matrix layers or pooled media, after 21 days of culture, 
and normalized to cell count within respective cases (n = 6/ condition). * indicates p < 0.01 
compared to GSNO-free cultures; # indicates p < 0.01 for 2D vs. 3D, at a given concentration of 
GSNO.
3.5. Elastin synthesis and deposition
The total elastin synthesized by AAA-SMCs (Fig. 2C; Table 2) was quantified as that 
deposited in the cell layers (i.e., matrix elastin) or released into the pooled media (i.e., 
19
tropoelastin). The benefits of exogenous NO to elastin deposition in cell matrix appeared to be 
dependent on the substrate type. Compared to GSNO-free controls, significantly higher matrix 
elastin was deposited within 3D cultures with GSNO addition, although matrix elastin deposition 
decreased in 2D cultures. GSNO stimulated tropoelastin release only within 3D cultures, 
although the amounts were two-orders of magnitude higher than matrix elastin (Table 2).
The matrix elastin yields (ratio of matrix elastin to the total elastin produced) within 2D AAA-
SMCs cultures were 0.4% and 0.08% with 0 and 100 nM GSNO additive-cultures, respectively. 
However, 3D cultures modestly enhanced matrix elastin yields in the absence and presence of 
GSNO (0.5% and 0.8%, respectively). Thus, elastic matrix yields improved by 10-fold in 3D 
cultures with the addition of GSNO, similar in trend to that observed for the total protein 
amounts.
3.6. sGAG and HA synthesis
Adding GSNO to AAA-SMC cultures increased sGAG deposition in matrix layers (2.73- and 
1.52- fold, respectively) and in pooled media (2.17- and 1.72- fold, respectively) within 2D and 
3D cultures, on a per cell basis (Fig. 2C), although the amounts were two orders of magnitude 
higher in pooled media. Compared to 2D cultures, 3D cultures appeared to promote sGAG 
release into pooled media or deposition within cell layers, on a per cell basis (Table 2). sGAG 
yield (ratio of matrix sGAG to the total sGAG produced) within 2D AAA-SMC cultures indicated 
that matrix yields were 0.9% and 2.3% in controls and GSNO-additive cultures, respectively. 
However, 3D cultures did not show any enhancement of matrix sGAG yields, in the presence or 
absence of GSNO.
GSNO addition modestly increased HA deposition in cell matrix on a per cell basis in both 
2D and 3D cultures (1.41- and 1.35- fold, respectively; Fig. 2C), with similar increases in HA 
release into the pooled media. When AAA-SMCs were cultured in 2D, the matrix HA yields (ratio 
of HA deposited in matrix to the total HA produced) were 1.6% and 1.7% within controls and 
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GSNO additive-cultures, respectively. However, 3D cultures modestly increased matrix HA 
yields, in the presence or absence of GSNO (2% and 1.9%, respectively).
Figure 3. (A) Fold-changes in LOX enzyme functional activity within cell matrix and pooled 
media of AAA-SMC cultures, quantified using an Amplex Red® fluorometric assay and 
quantified on a per cell basis. Cells were exposed to 100 nM GSNO while controls received no 
GSNO. (B) Desmosine levels in pooled media collected from 2D or 3D Hu-SMCs (black 
histograms) or AAA-SMC cultures (black histograms), over the 21-day period, in the presence 
or absence of GSNO. (C) iNOS protein expression was quantified from western blot analysis. 
Representative bands are shown in the insert for comparison. iNOS protein expression by AAA-
SMC cultures (white histograms) was normalized to that in 2D GSNO-free cultures of healthy 
SMCs (black histograms). (D) Similarly, the release of TIMP-1 into pooled media was quantified 
using a TIMP-1 ELISA assay. GSNO (0 or 100 nM) was supplemented to AAA-SMC cultures in 
2D (black histograms) or 3D (white histograms) cultures over 21 days. Data were analyzed 
using one-way ANOVA followed by Tukey’s HSD post-hoc testing, assuming unequal variance 
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and differences deemed significant for p < 0.05. Data shown represent mean ± standard error of 
quantified data and normalized to cell count within respective cases (n = 6 per condition).
3.7. LOX enzyme activity
While GSNO addition to 2D cultures did not induce a significant change in LOX activity 
within cell matrix, it induced a 2.55-fold increase within 3D cultures (Fig. 3A; p<0.01). LOX 
activity in matrix within 3D cultures was significantly higher (2.2-fold; p<0.01) than that in 2D 
cultures. LOX activity within pooled media from 3D cultures was 13.5-fold higher than that in 2D 
cultures in the absence of GSNO. Although adding GSNO to 3D cultures did not enhance LOX 
activity compared to controls, it significantly increased LOX activity within 2D cultures (14.9-fold; 
p<0.01).
3.8. Desmosine crosslink density
In healthy SMC cultures (Fig. 3B), desmosine levels were higher in 2D cultures than in 3D 
cultures (p<0.01), and GSNO offered no additional benefit in both 2D and 3D cultures. However, 
in AAA-SMC cultures, desmosine levels were significantly higher in controls compared to 
GSNO-receiving cultures (p<0.01), in both 2D and 3D. The basal levels of desmosine by AAA-
SMCs remained unaltered in both 3D and 2D cultures. Finally, significant difference in 
desmosine levels were noted between healthy and AAA derived SMCs, in 3D cultures receiving 
no GSNO (p<0.001).
3.9. iNOS expression and TIMP-1 release
To test if exogenously-delivered NO influenced iNOS protein expression in AAA-SMC 
cultures, western blot analysis was performed (Fig. 3C; bands in insert). The basal level of 
iNOS expression (2D control cultures) was significantly higher in AAA-SMCs compared to 
healthy counterparts (p<0.05). It was found that GSNO addition to 2D cultures significantly 
promoted iNOS protein expression in healthy SMCs, but not in 3D cultures. Expression of iNOS 
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by AAA-SMCs, on the other hand, was not modified by 2D or 3D cultures, and/or by GSNO 
addition.
No significant difference in TIMP-1 release was noted between 2D and 3D AAA-SMC 
cultures in controls (Fig. 3D). GSNO induced a 2.4-fold increase in TIMP-1 release in 3D 
cultures. While the basal levels of TIMP-1 release was significantly lower in AAA-SMCs 
compared to adult healthy aortic SMCs in 3D cultures[18], the levels were similar in the 
presence of 100 nM GSNO.
3.10. Elastin, iNOS, LOX and fibrillin gene expression
Elastin (ELN) gene expression in AAA-SMCs, both in 2D and 3D cultures, in the presence or 
absence of NO cues, was significantly lower compared to healthy SMCs (Fig. 4A). Such 
inhibited elastin gene expression levels in AAA-SMCs, compared to healthy SMCs, was in 
agreement with their respective protein expression levels of matrix elastin (Table 2). Similarly, 
within AAA-SMCs, elastin gene expression was significantly lower in 2D compared to that in 3D, 
in agreement with their protein expression levels. Surprisingly, elastin gene expression was 
significantly lower after GSNO addition, in contrast to tropoelastin and matrix elastin produced 
by these cells (Fig. 2, C-D).
The iNOS gene expression of healthy and AAA-SMCs were similar in 2D and significantly 
increased in 3D cultures for AAA-SMCs (Fig. 4A). Adding GSNO had no significant effect on 
iNOS gene expression in AAA-SMC cultures, suggesting that AAA-SMCs are sensitive to 
signaling from exogenous NO cues, similar to their healthy counterparts. LOX gene expression 
was significantly higher (6 to 10 -fold in 2D and 3D cultures, respectively) in AAA-SMCs 
compared to healthy SMCs, although adding GSNO suppressed such elevated levels (Fig. 4A), 
in contrast with the LOX functional activity (Fig. 3A). The baseline levels of fibrillin-1 (FBN) gene 
in AAA-SMCs was significantly higher compared to their healthy counterparts, although such 
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expression levels were significantly downregulated in 2D AAA-SMC cultures with GSNO 
addition (Fig. 4A).
Figure 4. (A) Lavik method (ΔΔCt method) was used for relative quantification of the fold 
changes in ELN, iNOS, LOX, and FBN genes in AAA-SMCs, after addition of GSNO (0 or 100 
nM) within 2D (black histograms) or 3D (white histograms) cultures for 21 days. The gene 
expressions obtained from qRT-PCR analysis within AAA-SMCs were first normalized to 
housekeeping gene (18S) expression within respective cultures, and further normalized to 
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respective gene expressions within healthy Hu-SMCs cultured under similar conditions. Data 
were analyzed using one-way ANOVA followed by Tukey’s HSD post-hoc testing, assuming 
unequal variance and differences deemed significant for p < 0.05. Data shown represent mean 
± standard error (n = 6 independent data points per condition). (B) Heat map showing the 
amounts of cytokines, chemokines, and MMPs/TIMPs released by healthy and AAA SMCs, in 
2D and 3D cultures, in the presence or absence of 100 nM GSNO, as measured using laser 
bead immunoassay.
3.11. Release of cytokines, chemokines, MMPs, and TIMPs
We quantified the baseline levels (2D - 0 nM) of cytokines, chemokines, MMPs and TIMPs 
released by healthy Hu-SMCs [Supplementary Fig. 2 (A: < 10 pg/mL; C: < 250 pg/mL; E: < 40 
ng/mL)] and adult human AAA-SMCs [Supplementary Fig. 2 (B: < 10 pg/mL; D: < 250 pg/mL; 
F: < 40 ng/mL)]. Their levels in 3D cultures, and in the presence of 100 nM GSNO were also 
shown in respective panels. The analytes released by SMCs were plotted on a log-scale using a 
heatmap function (Fig. 4B). MMPs and TIMPs were the most highly-expressed analytes 
compared to the cytokines (e.g., ILs). Benefits of GSNO delivery in healthy SMC cultures (both 
2D and 3D), appeared marginal with no significant modulation in ILs and MMPs release but 
significant increase in TIMPs release. However, in 3D AAA-SMC cultures, GSNO suppressed 
the release of several analytes (e.g., IFN-γ, MMPs-8, 9, 12, IL-8) compared to all other 
conditions, and some analytes were undetectable in most conditions (IL-1 and TNF-). A ten-
fold increase in IL-6 release by AAA-SMCs was found compared to healthy counterparts. 
Variations in analyte concentrations were observed across samples cultured in 2D vs. 3D 
environments; for instance, SMCs in 2D cultures had higher concentrations of MMP-2, MMP-12, 
TIMP-2, TIMP-3, and MCP-1, in both healthy and AAA-SMC cultures. In general, cytokine and 
MMPs production in both cell types appeared to be regulated by GSNO presence as well as 
culture substrate (2D vs. 3D).
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Supplementary Figure 2. Amounts of various cytokines and chemokines released by human 
healthy aortic SMCs (A, C, E) or aneurysmal SMCs (B, D, F) over 21 days, within 2D or 3D 
cultures, in the presence or absence of exogenous GSNO (100 nM). Data was obtained from 
multiplexing laser bead assays using respective supernatants pooled over the culture duration. 
Panels A and B depict the analytes detected within 0 – 10 pg/mL levels (low amounts), C and D 
depict analytes detected within 10 – 250 pg/mL levels (moderate amounts), and E and F depict 
analytes detected within 0.2 – 35 ng/mL levels (high amounts).
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3.12. Immunofluorescence labeling of matrix proteins
AAA-SMCs deposited detectable matrix elastin and fibulins-4 and 5 within 2D cultures over 
the 21-day period within control cultures (Fig. 5). However, fibrillin-1, critical for matrix elastin 
coacervation and crosslinking, was undetectable around the periphery of most cells. GSNO 
significantly promoted deposition of matrix elastin, fibrillin-1 and fibulins-4, 5, compared to 
controls.
Figure 5. Representative immunofluorescence images of AAA-SMC layers in 2D cultures, with 
or without GSNO, stained with respective primary antibodies for elastin, fibrillin-1, fibulin-4 and 
fibulin-5, and counterstained with DAPI for cell nuclei. A significant increase in the expression of 
all the proteins was noted in the presence of 100 nM GSNO. Scale bar: 100 m. For each 
treatment condition, at least three independent cell layers were imaged, with six random regions 
captured in each cell layer.
3.13. Cell mechanics using AFM
Single cell nanoindentation measurements were obtained to quantify the elastic modulus (E) 
of live SMCs under different culture conditions (Fig. 6; Supplementary Fig. 3). Representative 
phase-contrast images (Supplementary Fig. 3), heat maps of elastic moduli (Fig. 6A), and 
force-indentation curves (Fig. 6B) were shown for healthy and AAA SMCs, in the presence or 
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absence of GSNO. The average modulus of elasticity for AAA-SMCs (17.41±0.34 kPa) was 
significantly higher (1.6-fold; p<0.001) than for healthy SMCs (10.42±0.29 kPa), indicating an 
increase of stiffness in AAA-SMCs (Fig. 6C). Upon exposure to GSNO, the average modulus of 
elasticity for healthy SMCs decreased by 1.3-fold (healthy SMCs: 8.67±0.25 kPa, p<0.05; AAA-
SMCs: 13.03±0.35 kPa, p<0.05). Cell roughness measurements showed that AAA-SMCs were 
smoother than Hu-SMCs (Fig. 6D). GSNO addition significantly increased cell surface 
roughness in Hu-SMCs (p<0.01), and nearly doubled the roughness in AAA-SMCs, compared 
to respective controls. In GSNO presence, Hu-SMCs and AAA-SMCs had no significant 
differences in their surface roughness.
Figure 6. (A) Representative force maps of healthy Hu-SMCs (left panels) and AAA-SMCs 
(right panels) treated with 100 nM GSNO (lower panels). Background from petri dish was 
subtracted in these images. Representative force-indentation curves (B) and average Young’s 
Modulus (C) of these cells cultured on 2D substrates, in the presence or absence of 100 nM 
GSNO. The black dotted lines in (C) represent the arithmetic averages in respective cases, i.e., 
10.33 ± 0.2624 KPa for untreated Hu-SMCs (n = 605), 8.674 ± 0.2491 KPa for Hu-SMCs 
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receiving GSNO (n = 550), 17.41 ± 0.3405 KPa for untreated AAA-SMCs (n = 524), and 13.03 ± 
0.3498 KPa for AAA-SMCs receiving GSNO (n = 469). (D) The surface roughness parameters 
Rq and Ra in Hu-SMCs and AAA-SMCs, in the presence of absence of GSNO. Data were 
analyzed using one-way ANOVA followed by Tukey’s HSD post-hoc testing, assuming unequal 
variance and differences deemed significant for p < 0.05. Data shown represent mean ± 
standard error (n = 6 independent data points per condition).
Supplementary Figure 3. Elastic modulus of cells acquired from AFM analysis. Histograms of 
elastic modulus data and corresponding representative phase contrast images of healthy Hu-
SMCs (A, A-1), healthy Hu-SMCs treated with 100 nM GSNO (B, B-1), AAA-SMCs (C, C-1), and 
AAA-SMCs treated with 100 nM GSNO (D, D-1). Representative force-indentation curves (Hertz 
model fit) and corresponding elastic moduli measured from those curves for healthy Hu-SMCs 
(A-2), healthy Hu-SMCs treated with 100 nM GSNO (B-2), AAA-SMCs (C-2), and AAA-SMCs 
treated with 100 nM GSNO (D-2).
4. Discussion
In this study, we compared the differences and behaviors of human aneurysmal SMCs and 
their healthy counterpart with regard to cell proliferation, phenotypic and genotypic expression, 
transcriptomic analyses, immunofluorescence imaging, biomechanical characteristics, and their 
response to exogenously-delivered NO cues, as a therapeutic AAA treatment.
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Prior studies reported that adult human AAA-SMCs proliferated 4-fold over 16 days [27], 5-
fold over 21 days [28], or doubled every 5.3 days [29] in 2D cultures, which is significantly 
higher than that noted in our study. AAA-SMCs proliferated significantly slower compared to 
their healthy counterparts (Table 2), possibly due to diseased nature and/ or differences in the 
age of the donors. AAA-SMCs, derived from a relatively older patient, synthesized and 
deposited more proteins in 3D cultures compared to the healthy SMCs derived from a younger 
adult. Our results highlight the increased ability of aortic SMCs to proliferate, migrate and 
deposit ECM under diseased vascular conditions [30].
Despite the prominent role of elastin in aortic tissue homeostasis maintenance, 
quantification of elastin synthesized by human AAA-SMCs has received less attention. 
Tropoelastin, the precursor molecule to elastin, is encoded by a single copy of ELN gene in 
SMCs and fibroblasts. Tropoelastin amounts in human AAA extracts was reported to be 5-fold 
higher than that within normal human aortic tissues [22]. Our current study suggests that healthy 
Hu-SMCs produce higher amounts of tropoelastin and matrix elastin compared to their AAA 
counterparts. Adult human AAA-SMCs were shown to release ~10 pg of tropoelastin and 
deposited 0.02 pg of matrix elastin on a per cell basis in 2D cultures, in the absence of any 
external cues [28]. These amounts were significantly lower than what we observed, despite 
similarities in donor age, disease phenotype and culture duration. Numerous studies have 
shown that the significant changes in elastin protein within AAA ECM might be due to a related 
change in the gene expression levels [31; 32]. Similar to our observations here, a down-
regulation in elastin gene in AAA tissues was reported in a porcine model of induced AAA, 
compared to healthy counterparts [33].
Adult human AAA-SMCs in 2D cultures release significantly higher levels of GAGs (e.g., 
versican, perlecan, heparan sulfate, biglycans) compared to healthy aortic SMCs [34]. Although 
the various types of sGAGs released by AAA-SMCs were not individually identified in our study, 
we quantified the absolute amount of overall GAGs production by AAA-SMCs and found 
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multifold increases in HA release into pooled media and deposition into matrix within AAA-SMC 
cultures. The combined amount of elastin and GAGs, in both pooled media and cell matrix, 
constitute a small fraction of the total matrix, suggesting that in addition to elastin and GAGs, 
numerous other proteins such as collagens and proteoglycans, might have been released and 
deposited by AAA-SMCs within 2D and 3D cultures.
Such deposited elastin precursors are crosslinked in the presence of LOX enzyme, resulting 
in the formation of desmosine and isodesmosine linkages between lysine molecules on elastin 
molecules [35]. Thus, the final crosslinked elastic fibers typically have a microfibril sheath 
surrounding the core elastin molecules. Additional stimulation such as alternate scaffold design, 
elastogenic scaffold material, exogenous LOX, and mechanical stimuli might be necessary to 
coax the AAA-SMCs to enhance matrix elastin yields. Although it is interesting to note that AAA-
SMCs produce LOX which is functionally active, the levels of LOX functional activity within AAA-
SMC cultures are at least two orders of magnitude lower than that quantified within healthy SMC 
cultures (Table 2), on a per cell basis. This difference might be due to the age difference in the 
donor sources of these cell lines, as well as the phenotypic differences between healthy versus 
AAA cells. Studies have shown that in addition to regulating vascular SMC phenotype 
(proliferation, migration), LOX also plays a primary role in ECM crosslinking such as collagens, 
elastin and GAGs [36]. However, under diseased conditions such as aneurysms, characterized 
by remarkable degradation and ECM remodeling, LOX activity and expression is significantly 
reduced. While it is not clear whether reduction in LOX levels contribute to the onset of the 
pathogenesis of these diseases or vice versa, numerous AAA-induced animal models 
demonstrate strong correlation between LOX expression reduction and disease progression 
[37].
Desmosine levels in healthy human arterial tissues was noted to be at least 9-fold higher 
than that in AAA segments [22], and reduced desmosine levels were reported in dissecting 
AAAs [38], suggesting diminished levels of mature, crosslinked elastin in AAA tissues. We here 
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measured desmosine levels in the supernatants to determine if sufficient levels of desmosine is 
being produced that could crosslink tropoelastin in vitro within SMC cultures.
Although vascular NO plays an important role in regulating SMC functions such as 
vasodilation, survival, gene regulation, and quiescence phenotype, the harmful role of higher 
NO levels in the pathogenesis of aneurysms has been documented [39; 40; 41]. Specifically, 
iNOS-stimulated NO release from vascular SMCs was shown to participate in elastin 
degradation and disruption of vascular ECM [42]. Our observations agree with previous reports 
that experimental or human AAA-derived tissues had higher iNOS levels compared to control 
tissues where iNOS could barely be detected [40; 43]. TIMPs-1, 2 regulate ECM remodeling in 
vasculature by controlling the levels and activity of MMPs. In agreement with our results, no 
significant differences in TIMP-1 levels (Western blotting) within tissue sections isolated from 
AAA patients and their healthy counterparts were observed [44].
Localized inflammation contributes to weakening of aorta due to imbalances in ECM levels 
[45]. This has prompted research focused on regulating the production of inflammatory 
molecules as a therapeutic intervention in lieu of invasive surgical approaches [46]. The 
concentrations noted for MMPs/ TIMPs in our study broadly falls in the range reported by others 
and our previous work [18; 27]. Given the apparent differences in cytokine production between 
AAA and healthy SMCs, our data supports the prevailing notion that cytokine stimulation via 
paracrine or autocrine signaling may in turn modulate MMP activation [47]. Although it has been 
suggested that NO can influence the production of some cytokines and chemokines [48], we did 
not see any differences. In summary, our data is consistent with the inflammatory patterns seen 
in AAA subjects and suggests that NO presence modulates MMP production in a potentially 
therapeutic manner.
In addition to alterations in composition and functionality of vascular endothelium and ECM, 
changes in cell stiffness might also contribute to vascular tissue stiffness in AAAs, 
atherosclerosis and hypertensive conditions. The stiffness (~30 kPa) of hypertensive aorta-
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derived SMCs, as measured by AFM nano-indentation, was reported to be two-fold higher than 
that of normal aorta (~14 kPa), and such stiffness was mediated by cytoskeletal proteins [49]. 
Vascular SMCs from old male monkeys exhibited much higher stiffness than their younger 
counterparts (42 kPa vs. 13 kPa) [50]. The elastic modulus of primary adult male rat arteriole-
derived SMCs (~13.5 kPa) decreased by 38% upon exposure to NO donor PANOate, most 
likely due to remodeling of actin cytoskeleton network [51]. Marfan vascular SMCs were two-fold 
stiffer than healthy human SMCs, as measured by AFM, most likely due to higher focal 
adhesion kinase protein and actin stress fibers expression [52]. Here, we report for the first time 
on the stiffness and surface roughness of human aortic SMCs from healthy and AAA tissues, 
using AFM nano-indentation of live cells. Our results show that (i) elastic modulus of healthy Hu-
SMCs is lower than that in rats and monkeys; (ii) human AAA-SMCs have higher stiffness and 
lower surface roughness compared to healthy Hu-SMCs; and (iii) human AAA-SMCs had 
significantly lower stiffness compared to hypertensive rat SMCs or aged monkey SMCs.
Our results support our hypothesis that AAA-SMCs do respond to exogenous NO cues to 
modulate cell proliferation and protein synthesis in 3D cultures. We have recently shown that 
healthy Hu-SMCs produced significantly higher amounts of tropoelastin and matrix elastin in the 
presence of 100 nM GSNO, and that an optimal 100 nM GSNO promoted sGAG deposition in 
matrix layers but not their release into the pooled media, within 3D Hu-SMC cultures [18].
An increase in LOX functional activity within 3D AAA-SMC cultures in GSNO presence (Fig. 
3), and significantly higher deposition of fibrillar forms of elastic matrix-associated proteins such 
as fibrillin-1, and fibulins- 4, 5 (Fig. 5), is highly encouraging for therapeutic tissue engineering 
and in situ elastin regeneration. Increased levels of LOX functional activity by exogenous GSNO 
might partially explain the increases in matrix elastin, GAGs, and tropoelastin in 3D AAA-SMC 
cultures. Similar increases in tropoelastin but not desmosine levels by human and rat AA-SMCs 
were reported by others [22; 53]. Higher amounts of GSNO (> 100 nM) could possibly elevate 
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desmosine levels in 3D AAA-SMC cultures, which further enhances elastin crosslinking and 
maturation.
The increased levels of TIMP-1 in AAA-SMC 3D cultures in the presence of GSNO is 
encouraging in modulating further degradation of vascular ECM by MMPs under diseased 
conditions. GSNO induced significant increases in matrix elastin deposition in 3D cultures and 
reduced MMP-9 concentration by over 50% in all cases (2D/3D AAA-SMC cultures), compared 
to healthy controls. Given that the upregulation of MMP-9 is linked to the degradation of the 
aortic ECM, our results are encouraging as they suggest a therapeutic benefit in the 
supplementation of exogenous NO [54]. Similar trend was noted for MMP-2 in nearly all cases 
(excluding 3D AAA-SMC cultures). Similar patterns in MMP downregulation were observed in 
eNOS gene–transfected cells [55], and it has been suggested this pathway is regulated by 
guanylyl-cyclase dependent and independent pathways [56]. NO appeared to have little effect 
on TIMPs release across most cases. In agreement with literature, we noticed significantly 
higher IL-6 levels by AAA-SMCs. And finally, delivering exogenous NO significantly lessened 
AAA-SMC stiffness and enhanced surface roughness, possibly via modulation of cytoskeletal 
and surface proteins, respectively. We postulate that changes in stiffness beginning at single 
cell level might contribute to changes in vascular tone and functionality of aneurysmal vessels 
and delivering GSNO could be explored as a therapeutic strategy. Taken together, results 
confirm our hypothesis that exogenous NO delivery to AAA-SMCs might help to promote protein 
synthesis, release and deposition within 3D cultures, in addition to regulating their proliferation.
In conclusion, we established the baseline differences between adult human AAA and 
healthy SMCs, in terms of their size, proliferation, matrix and associated proteins synthesis and 
deposition, release of cytokines/ chemokines/ MMPs/ TIMPs, changes in genotype of 
elastogenic markers, and stiffness and roughness. We demonstrated that exogenously 
delivering NO via GSNO offers an effective strategy to enhance AAA-SMC functionality. These 
outcomes might help in further designing tissue engineering and regenerative medicine-based 
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approaches, consisting of 3D scaffolds and localized drug delivery options, specifically for in situ 
elastin regeneration and remodeling to arrest aneurysm progression.
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